ACT Brief: Governance-Driven eCOA Acceleration, Site Operations Innovation, and New Momentum for Earlier CAR-T

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• A new feature article examines how robust relational governance between eCOA vendors and sponsor–CRO teams is becoming essential for fast, high-quality study launches. Clear communication frameworks, empowered customer success teams, and continuous learning cycles are helping organizations reduce issues, improve data quality, and accelerate trial startup across entire portfolios.
• In a new video interview from the 2025 Veeva R&D and Quality Summit, AMR Clinical’s Nancy Cleverley outlines the biggest opportunities to strengthen site operations across its 30-site network. She describes how sponsors and CROs can reduce burden, support better participant experiences, and enable easier data sharing and real-time collaboration as trial execution models continue to evolve.
• And new CARTITUDE-4 trial data shows that earlier use of Johnson & Johnson’s Carvykti is producing durable, treatment-free remissions lasting well beyond 30 months for many relapsed or refractory multiple myeloma patients. The findings build on real-world evidence from more than 9,000 treated patients and signal a meaningful shift toward deploying CAR-T therapy sooner in the treatment pathway.

That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.